Table 1. Clinical efficacy parameters at baseline and at the end of treatment (median and IQR are presented)
| Week 0 | Week 12 | p | |
|---|---|---|---|
| DAS28 | 6.36 (5.98-6.78) | 4.73 (3.85-5.64) | <0.0001 |
| SJC | 7 (5–0) | 3 (1-4) | <0.0001 |
| TJC | 17 (13–20) | 14 (3–20) | 0.0563 |
| General health, mm | 53 (44–70) | 38.5 (25–54) | 0.0001 |
| ESR, mm/h | 35.5 (32–50) | 14.5 (10–30) | <0.0001 |
| Activity by patient, mm | 57 (50–65) | 38 (21–59) | 0.0198 |
| Activity by physician, mm | 55 (37–60) | 35.5 (15–5 ) | <0.0001 |
| Morning stiffness, min | 330 (180–1440) | 152.5 (60–290) | 0.018 |